VNDA
Vanda Pharmaceuticals Inc. · Healthcare
Insiders sold $2.6M of Vanda Pharmaceuticals Inc. in the last 12 months and bought none
VNDA over the last year
VNDA after insider buys
3 months after each buy, from the first price a copier could get.
10 buys since 2025 with 3 months of prices.
Every filing
104 insider filings since 2016, newest first
Phaedra Chrousos · Director
Aranthan Jones II · Chief Corp. Affairs Officer
Mihael Hristos Polymeropoulos · President and CEO
Timothy Williams · SVP and General Counsel
Timothy Williams · SVP and General Counsel
Joakim Wijkstrom · SVP and CMO
Mihael Hristos Polymeropoulos · President and CEO
Kevin Patrick Moran · SVP, CFO and Treasurer
Aranthan Jones II · Chief Corp. Affairs Officer
Gunther Birznieks · SVP, Business Development
Thomas Watkins · Director
Richard W Dugan · Director
Mihael Hristos Polymeropoulos · President and CEO
Joakim Wijkstrom · SVP and CMO
Timothy Williams · SVP and General Counsel
Aranthan Jones II · Chief Corp. Affairs Officer
Aranthan Jones II · Chief Corp. Affairs Officer
Thomas Watkins · Director
Richard W Dugan · Director
Timothy Williams · SVP and General Counsel
Mihael Hristos Polymeropoulos · President and CEO
James Patrick Kelly · EVP and CFO
Gunther Birznieks · SVP, Business Development
Mihael Hristos Polymeropoulos · President and CEO
James Patrick Kelly · EVP and CFO
Gunther Birznieks · SVP, Business Development
Mihael Hristos Polymeropoulos · President and CEO
Richard W Dugan · Director
Timothy Williams · SVP and General Counsel
Mihael Hristos Polymeropoulos · President and CEO
Mihael Hristos Polymeropoulos · President and CEO
James Patrick Kelly · EVP and CFO
Gunther Birznieks · SVP, Business Development
Gian Piero Reverberi · SVP and Chief Commercial Officer
Gunther Birznieks · SVP, Business Development
James Patrick Kelly · EVP and CFO
Mihael Hristos Polymeropoulos · President and CEO
Mihael Hristos Polymeropoulos · President and CEO
James Patrick Kelly · EVP and CFO
Richard L. Gulino · SVP, GC, Sec.
Gunther Birznieks · SVP, Business Development
Mihael Hristos Polymeropoulos · President and CEO
James Patrick Kelly · EVP and CFO
Richard L. Gulino · SVP, GC, Sec.
Gunther Birznieks · SVP, Business Development
Paolo Baroldi · SVP and Chief Medical Officer
Richard L. Gulino · SVP, GC, Sec.
James Patrick Kelly · SVP, CFO and Treasurer
Mihael Hristos Polymeropoulos · President and CEO
James E Flynn · Possible Member of 10% Group, 10%
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.